Search

Your search keyword '"Zu, Youli"' showing total 643 results
Start Over Author "Zu, Youli"
643 results on '"Zu, Youli"'

101. Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning

Author

Albitar, Maher, primary, Xu-Monette, Zijun Yidan, additional, Shahbaba, Babak, additional, De Dios, Ivan, additional, Wang, Yingjun, additional, Manman, Deng, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Bhagat, Govind, additional, Dybkær, Karen, additional, Tam, Wayne, additional, Hsi, Eric D., additional, Ponzoni, Maurilio, additional, Ferreri, Andres JM, additional, Moller, Michael, additional, Piris, Miguel A., additional, Van Krieken, Joannes H.J.M., additional, Zu, Youli, additional, Ma, Wanlong, additional, Kantarjian, Hagop M., additional, Li, Yong, additional, and Young, Ken H., additional

Published
2019
Full Text
View/download PDF

102. MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup

Author

Albitar, Maher, primary, Zijun, Xu‐Monette Y, additional, Wang, Yingjun, additional, Manman, Deng, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Bhagat, Govind, additional, Dybkær, Karen, additional, Tam, Wayne, additional, Hsi, Eric D., additional, Ponzoni, Maurilio, additional, Ferreri, Andres JM, additional, Møller, Michael Boe, additional, Piris, Miguel A., additional, Krieken, Han van, additional, De Dios, Ivan, additional, Zu, Youli, additional, Winter, Jane N, additional, Kantarjian, Hagop M., additional, Li, Yong, additional, and Young, Ken H., additional

Published
2019
Full Text
View/download PDF

105. Rapid Detection of Mycoplasma-Infected Cells by an ssDNA Aptamer Probe

Author

Liu, Yanting, primary, Jiang, Wenqi, additional, Yang, Shuanghui, additional, Hu, Jianzhong, additional, Lu, Hongbin, additional, Han, Wei, additional, Wen, Jianguo, additional, Zeng, Zihua, additional, Qi, Jianjun, additional, Xu, Ling, additional, Zhou, Haijun, additional, Sun, Hongguang, additional, and Zu, Youli, additional

Published
2019
Full Text
View/download PDF

109. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma

Author

Zu Youli, Wong Michael S, Bagaria Hitesh G, and Zhao Nianxi

Subjects
Biotechnology, TP248.13-248.65, Medical technology, R855-855.5
Abstract

Abstract Background Many in vitro studies have demonstrated that silencing of cancerous genes by siRNAs is a potential therapeutic approach for blocking tumor growth. However, siRNAs are not cell type-selective, cannot specifically target tumor cells, and therefore have limited in vivo application for siRNA-mediated gene therapy. Results In this study, we tested a functional RNA nanocomplex which exclusively targets and affects human anaplastic large cell lymphoma (ALCL) by taking advantage of the abnormal expression of CD30, a unique surface biomarker, and the anaplastic lymphoma kinase (ALK) gene in lymphoma cells. The nanocomplexes were formulated by incorporating both ALK siRNA and a RNA-based CD30 aptamer probe onto nano-sized polyethyleneimine-citrate carriers. To minimize potential cytotoxicity, the individual components of the nanocomplexes were used at sub-cytotoxic concentrations. Dynamic light scattering showed that formed nanocomplexes were ~140 nm in diameter and remained stable for more than 24 hours in culture medium. Cell binding assays revealed that CD30 aptamer probes selectively targeted nanocomplexes to ALCL cells, and confocal fluorescence microscopy confirmed intracellular delivery of the nanocomplex. Cell transfection analysis showed that nanocomplexes silenced genes in an ALCL cell type-selective fashion. Moreover, exposure of ALCL cells to nanocomplexes carrying both ALK siRNAs and CD30 RNA aptamers specifically silenced ALK gene expression, leading to growth arrest and apoptosis. Conclusions Taken together, our findings indicate that this functional RNA nanocomplex is both tumor cell type-selective and cancer gene-specific for ALCL cells.

Published
2011
Full Text
View/download PDF

111. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

Author

Bollard, Catherine M., primary, Tripic, Tamara, additional, Cruz, Conrad Russell, additional, Dotti, Gianpietro, additional, Gottschalk, Stephen, additional, Torrano, Vicky, additional, Dakhova, Olga, additional, Carrum, George, additional, Ramos, Carlos A., additional, Liu, Hao, additional, Wu, Meng-Fen, additional, Marcogliese, Andrea N., additional, Barese, Cecilia, additional, Zu, Youli, additional, Lee, Daniel Y., additional, O’Connor, Owen, additional, Gee, Adrian P., additional, Brenner, Malcolm K., additional, Heslop, Helen E., additional, and Rooney, Cliona M., additional

Published
2018
Full Text
View/download PDF

112. DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement

Author

Mai, Junhua, primary, Li, Xin, additional, Zhang, Guodong, additional, Huang, Yi, additional, Xu, Rong, additional, Shen, Qi, additional, Lokesh, Ganesh L., additional, Thiviyanathan, Varatharasa, additional, Chen, Lingxiao, additional, Liu, Haoran, additional, Zu, Youli, additional, Ma, Xiaojing, additional, Volk, David E., additional, Gorenstein, David G., additional, Ferrari, Mauro, additional, and Shen, Haifa, additional

Published
2018
Full Text
View/download PDF

114. Acute leukemia immunohistochemistry: a systematic diagnostic approach

Author

Olsen, Randall J., Chang, Chung-Che, Herrick, Jennifer L., Zu, Youli, and Ehsan, Aamir

Subjects
Acute leukemia -- Diagnosis, Acute leukemia -- Care and treatment, Acute leukemia -- Research, Immunohistochemistry -- Usage
Abstract

Context.--The diagnosis and classification of leukemia is becoming increasingly complex. Current classification schemes incorporate morphologic features, immunophenotype, molecular genetics, and clinical data to specifically categorize leukemias into various subtypes. Although sophisticated methodologies are frequently used to detect characteristic features conferring diagnostic, prognostic, or therapeutic implications, a thorough microscopic examination remains essential to the pathologic evaluation. Detailed blast immunophenotyping can be performed with lineage- and maturation-specific markers. Although no one marker is pathognomonic for one malignancy, a well-chosen panel of antibodies can efficiently aid the diagnosis and classification of acute leukemias. Objective.--To review important developments from recent and historical literature. General immunohistochemical staining patterns of the most commonly encountered lymphoid and myeloid leukemias are emphasized. The goal is to discuss the immunostaining of acute leukemias when flow cytometry and genetic studies are not available. Data Sources.--A comprehensive review was performed of the relevant literature indexed in PubMed (National Library of Medicine) and referenced medical texts. Additional references were identified in the reviewed manuscripts. Conclusions.--Immunophenotyping of blasts using an immunohistochemical approach to lymphoid and myeloid malignancies is presented. Initial and subsequent additional antibody panels are suggested to confirm or exclude each possibility in the differential diagnosis and a general strategy for diagnostic evaluation is discussed. Although the use of immunohistochemistry alone is limited and evaluation by flow cytometry and genetic studies is highly recommended, unavoidable situations requiring analysis of formalin-fixed tissue specimens arise. When performed in an optimized laboratory and combined with a careful morphologic examination, the immunohistochemical approach represents a useful laboratory tool for classifying various leukemias., Historically, acute leukemia (AL) classifications used blast morphology and cytochemical stains to categorize the diseases broadly into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). (1-4) The current World [...]

Published
2008

115. Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation

Author

Ito, Masanori, Zhao, Nianxi, Zeng, Zihua, Zhou, Xiaobo, Chang, Chung-Che, and Zu, Youli

Subjects
hemic and lymphatic diseases, IL-2 signaling, tumor microenvironment, Article, anaplastic large cell lymphoma (ALCL), CD25/IL-2 receptor, extracellular signal-regulated kinases (ERK1/2)
Abstract

In addition to intrinsic genetic alterations, the effects of the extrinsic microenvironment also play a pathological role in cancer development. Altered chemokine/cytokine networks in the tumor microenvironment may contribute to the dysregulation of cellular functions in cancer cells. Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma caused by abnormal expression of anaplastic lymphoma kinase due to a chromosomal translocation. Notably, ALCL cells are also characterized by high-level expression of the high-affinity IL-2 receptor subunit CD25 on the cell surface. However, whether the IL-2/IL-2 receptor functions in ALCL cells and how this signaling affects the tumor remain unclear. In this study, we treated cultured ALCL cells with exogenous IL-2 and examined changes in cellular function and signaling pathways. IL-2 stimulated cell growth and augmented activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway. Additionally, IL-2 enhanced lymphoma cell survival by overcoming kinase inhibitor U0126-induced growth arrest and apoptosis. Subsequently, to identify the potential source of IL-2 for lymphoma cells in vivo, we performed gene expression and immunochemical analyses. RT-PCR revealed no IL-2 gene expression in cultured ALCL cells and ruled out the possibility of an IL-2 autocrine loop. Interestingly, immunostaining of lymphoma tumor tissues showed IL-2 protein expression in background cells within tumor tissue, but not in ALCL cells. Our findings demonstrate that IL-2 signaling plays a functional role in ALCL cells, and enhances lymphoma cell survival by increasing activation of the ERK1/2 pathway.

Published
2011

116. Polymorphisms in TGF[beta] and TNF[alpha] are associated with the myelodysplastic syndrome phenotype

Author

Powers, Martin P., Nishino, Ha, Luo, Yamin, Raza, Alina, Vanguri, Amulya, Rice, Lawrence, Zu, Youli, and Chang, Chung-Che "Jeff"

Subjects
Genetic polymorphisms -- Research, Myelodysplastic syndromes -- Risk factors, Myelodysplastic syndromes -- Genetic aspects, Myelodysplastic syndromes -- Research, Transforming growth factors -- Health aspects, Transforming growth factors -- Research, Tumor necrosis factor -- Health aspects, Tumor necrosis factor -- Research
Abstract

* Context.--Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis, excessive apoptosis, and the aberrant expression of a number of cytokines. The genes encoding these cytokines are significantly polymorphic. It is unknown whether these cytokine polymorphisms are associated with, and may therefore be playing a role in the pathogenesis of, MDS. Objective.--To determine if certain polymorphisms in the tumor necrosis factor [alpha] (TNF-[alpha]) and transforming growth factor [beta] (TGF-[beta]) cytokines are overrepresented in a cohort of patients with MDSs. Design.--DNA was isolated from the peripheral blood or bone marrow aspirate of 21 patients with MDS. The genotypes for 4 different polymorphisms, 2 in TNF[alpha] and 2 in TGF[beta]1, were determined using single-specific-primer polymerase chain reaction. The allele and genotype frequencies were compared with similar populations in the National Cancer Institute SNP500 database. Results.--In our MDS population, the--308A/A genotype of the TNF[alpha] gene and the TGF[beta]1 allele +29T and genotype + 29T/T, each associated with higher levels of expression, were overrepresented in our MDS population. Conclusions.--Polymorphisms associated with increased expression in the cytokines TNF[alpha] and TGF[beta]1 are overrepresented in the MDS population suggesting that increased TNF-[alpha] and TGF-[beta]1 activity may contribute to the susceptibility and/or pathogenesis of MDS. Further studies with larger sample sizes are warranted to confirm our observation. (Arch Pathol Lab Med. 2007;131:1789-1793), The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, multilineage dysplasia, peripheral cytopenias, and susceptibility to leukemia. (1) Demonstrating a varied [...]

Published
2007

117. Primary central nervous system histiocytic sarcoma with relapse to mediastinum: a case report and review of the literature

Author

Cao, Ming, Eshoa, Camellia, Schultz, Christopher, Black, Jennifer, Zu, Youli, and Chang, Chung-Che

Subjects
Nervous system cancer -- Case studies -- Complications and side effects, Cancer -- Relapse, Health
Abstract

* Histiocytic sarcoma is a rare, malignant neoplasm of the lymphohematopoietic system that usually occurs in the skin, lymph node, and intestinal tract. Here we describe a unique case of [...]

Published
2007

118. A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells

Author

Liu, Haoran, primary, Mai, Junhua, additional, Shen, Jianliang, additional, Wolfram, Joy, additional, Li, Zhaoqi, additional, Zhang, Guodong, additional, Xu, Rong, additional, Li, Yan, additional, Mu, Chaofeng, additional, Zu, Youli, additional, Li, Xin, additional, Lokesh, Ganesh L., additional, Thiviyanathan, Varatharasa, additional, Volk, David E., additional, Gorenstein, David G., additional, Ferrari, Mauro, additional, Hu, Zhongbo, additional, and Shen, Haifa, additional

Published
2018
Full Text
View/download PDF

119. <html>Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma</html>

Author

Orazi, Attilio, Ponzoni, Maurilio, Richards, Kristy L., Ferreri, Andrés J.M., Winter, Jane N., Tzankov, Alexandar, van Krieken, J. Han, Parsons, Ben M., Deng, Lijuan, Manyam, Ganiraju C., Choi, William W.L., Montes-Moreno, Santiago, Zhang, Li, Young, Ken H., Visco, Carlo, Møller, Michael B., Wang, Xiaoxiao, Piris, Miguel A., Hu, van den Shimin, Zu, Youli, Hsi, Eric D., Chiu, April, Bhagat, Govind, Xu-Monette, Zijun Y., Dybkær, Karen, Huh, Jooryung, Ye, Qing, and Medeiros, L. Jeffrey

Subjects
immune system diseases, hemic and lymphatic diseases
Abstract

Double-hit B-cell lymphoma is a common designation for a group of tumors characterized by concurrent translocations of MYC and BCL2, BCL6, or other genes. The prognosis of concurrent MYC and BCL6 translocations is not well known. In this study, we assessed rearrangements and expression of MYC, BCL2 and BCL6 in 898 patients with de novo diffuse large B-cell lymphoma treated with standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). Neither BCL6 translocation alone (more frequent in activated B-cell like diffuse large B-cell lymphoma) nor in combination with MYC translocation (observed in 2.0% of diffuse large B-cell lymphoma) predicted poorer survival in diffuse large B-cell lymphoma patients. Diffuse large B-cell lymphoma patients with MYC/BCL6 co-expression did have significantly poorer survival, however, MYC/BCL6 co-expression had no effect on prognosis in the absence of MYC/BCL2 co-expression, and had no additive impact in MYC+/BCL2+ cases. The isolated MYC+/BCL6+/BCL2− subset, more frequent in germinal center B-cell like diffuse large B-cell lymphoma, had significantly better survival compared with the isolated MYC+/BCL2+/BCL6− subset (more frequent in activated B-cell like diffuse large B-cell lymphoma). In summary, diffuse large B-cell lymphoma patients with either MYC/BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis; MYC expression levels should be evaluated simultaneously; and double-hit B-cell lymphoma needs to be refined based on the specific genetic abnormalities present in these tumors.

Published
2016
Full Text
View/download PDF

124. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary?

Author

Ok, Chi Young, Ye, Qing, Li, Ling, Manyam, Ganiraju C., Deng, Lijuan, Goswami, Rashmi R., Wang, Xiaoxiao, Montes Moreno, Santiago, Visco, Carlo, Tzankov, Alexandar, Dybkaer, Karen, Zhang, Li, Abramson, Jeremy, Sohani, Aliyah R., Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Piris Pinilla, Miguel Ángel, Richards, Kristy L., and Universidad de Cantabria

Subjects
immune system diseases, hemic and lymphatic diseases, neoplasms
Abstract

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.

Published
2015

125. <html>Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma</html>

Author

Young, Ken H., Piris, Miguel A., Ferreri, Andrés J.M., van Krieken, J. Han, Huh, Jooryung, Ponzoni, Maurilio, Xu-Monette, Zijun Y., Zu, Youli, Hsi, Eric D., Richards, Kristy L., Jeffrey Medeiros, L., Møller, Michael B., Ok, Chi Young, Montes-Moreno, Santiago, Manyam, Ganiraju C., Chiu, April, Dybkaer, Karen, Tzankov, Alexandar, Wang, Jinfen, Parsons, Ben M., Visco, Carlo, Choi, William W.L., Winter, Jane N., Li, Ling, Pham, Lan V., Zhang, Mingzhi, Sun, Ruifang, Orazi, Attilio, and Bhagat, Govind

Subjects
animal structures, hemic and lymphatic diseases
Abstract

Dysregulated NF-κB signaling is critical for lymphomagenesis. The regulation, function, and clinical relevance of c-Rel/NF-κB activation in diffuse large B-cell lymphoma (DLBCL) have not been well studied. In this study we analyzed the prognostic significance and gene-expression signature of c-Rel nuclear expression as surrogate of c-Rel activation in 460 patients with de novo DLBCL. Nuclear c-Rel expression, observed in 137 (26.3%) DLBCL patients frequently associated with extranoal origin, did not show significantly prognostic impact in the overall- or germinal center B-like-DLBCL cohort, likely due to decreased pAKT and Myc levels, up-regulation of FOXP3, FOXO3, MEG3 and other tumor suppressors coincided with c-Rel nuclear expression, as well as the complicated relationships between NF-κB members and their overlapping function. However, c-Rel nuclear expression correlated with significantly poorer survival in p63+ and BCL-2− activated B-cell-like-DLBCL, and in DLBCL patients with TP53 mutations. Multivariate analysis indicated that after adjusting clinical parameters, c-Rel positivity was a significantly adverse prognostic factor in DLBCL patients with wild type TP53. Gene expression profiling suggested dysregulations of cell cycle, metabolism, adhesion, and migration associated with c-Rel activation. In contrast, REL amplification did not correlate with c-Rel nuclear expression and patient survival, likely due to co-amplification of genes that negatively regulate NF-κB activation. These insights into the expression, prognostic impact, regulation and function of c-Rel as well as its crosstalk with the p53 pathway underscore the importance of c-Rel and have significant therapeutic implications.

Published
2015
Full Text
View/download PDF

126. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary

Author

Richards, Kristy L., Zhang, Shanxiang, Ye, Qing, Orazi, Attilio, Zu, Youli, Abramson, Jeremy, Zhang, Li, Bhagat, Govind, van Krieken, J. Han, Xu-Monette, Zijun Y., Visco, Carlo, Ok, Chi Young, Wang, Xiaoxiao, Li, Ling, Hsi, Eric D., Deng, Lijuan, Tzankov, Alexandar, Goswami, Rashmi R., Chiu, April, Piris, Miguel A., Xu, Mina, Sohani, Aliyah R., Ponzoni, Maurilio, Winter, Jane N., Montes-Moreno, Santiago, Manyam, Ganiraju C., Choi, William W.L., Ferreri, Andrés J.M., Dybkaer, Karen, Huh, Jooryung, Møller, Michael B., and Parsons, Ben M.

Subjects
immune system diseases, hemic and lymphatic diseases, neoplasms
Abstract

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.

Published
2015
Full Text
View/download PDF

127. SDF-1α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II

Author

Choi, Dong Soon, Stark, Daniel J., Raphael, Robert M., Wen, Jianguo, Su, Jing, Zhou, Xiaobo, Chang, Chung-Che, and Zu, Youli

Subjects
Male, Myosin Type II, rho-Associated Kinases, Blotting, Western, Mesenchymal Stem Cells, Middle Aged, Article, Chemokine CXCL12, Phosphatidylinositol 3-Kinases, Bone Marrow, Case-Control Studies, Cell Adhesion, Tumor Cells, Cultured, Humans, Female, Phosphorylation, Multiple Myeloma, rhoA GTP-Binding Protein, Cell Proliferation, Signal Transduction
Abstract

Multiple myeloma (MM) is a B lymphocyte malignancy that remains incurable despite extensive research efforts. This is due, in part, to frequent disease recurrences associated with the persistence of myeloma cancer stem cells (mCSCs). Bone marrow mesenchymal stromal cells (BMSCs) play critical roles in supporting mCSCs through genetic or biochemical alterations. Previously, we identified mechanical distinctions between BMSCs isolated from MM patients (mBMSCs) and those present in the BM of healthy individuals (nBMSCs). These properties of mBMSC contributed to their ability to preferentially support mCSCs. To further illustrate mechanisms underlying the differences between mBMSCs and nBMSCs, here we report that (i) mBMSCs express an abnormal, constitutively high level of phosphorylated Myosin II, which leads to stiffer membrane mechanics, (ii) mBMSCs are more sensitive to SDF-1α-induced activation of MYL2 through the G(i./o)-PI3K-RhoA-ROCK-Myosin II signaling pathway, affecting Young's modulus in BMSCs and (iii) activated Myosin II confers increased cell contractile potential, leading to enhanced collagen matrix remodeling and promoting the cell-cell interaction between mCSCs and mBMSCs. Together, our findings suggest that interfering with SDF-1α signaling may serve as a new therapeutic approach for eliminating mCSCs by disrupting their interaction with mBMSCs.

Published
2014

129. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma

Author

Zhang, Mingzhi, primary, Xu-Monette, Zijun Y., additional, Li, Ling, additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Wang, Jing, additional, Montes-Moreno, Santiago, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Parsons, Ben M., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, Pham, Lan V., additional, and Young, Ken H., additional

Published
2016
Full Text
View/download PDF

131. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Deng, Qipan, additional, Manyam, Ganiraju C., additional, Tzankov, Alexander, additional, Li, Ling, additional, Xia, Yi, additional, Wang, Xiao-xiao, additional, Zou, Dehui, additional, Visco, Carlo, additional, Dybkær, Karen, additional, Li, Jun, additional, Zhang, Li, additional, Liang, Han, additional, Montes-Moreno, Santiago, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Parsons, Ben M., additional, Møller, Michael B., additional, Wang, Sa A., additional, Miranda, Roberto N., additional, Piris, Miguel A., additional, Winter, Jane N., additional, Medeiros, L. Jeffrey, additional, Li, Yong, additional, and Young, Ken H., additional

Published
2016
Full Text
View/download PDF

132. Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large Bcell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy:A Report from the International DLBCL Rit

Author

Xu-Monette, Z Y, Møller, Michael B, Tzankov, A, Montes-Moreno, S, Hu, Wenwei, Manyam, Ganiraju C, Kristensen, Louise, Fan, Lei, Visco, Carlo, Dybkær, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Bhagat, G, Richards, Kristy L, Hsi, E D, Choi, William W.L., van Krieken, J H, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, A J M, Wu, Lin, Winter, Jane N., Piris, M A, Medeiros, L J, and Young, Ken H

Published
2014

133. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

Author

Xu-Monette, Zijun Y., primary, Zhang, Shanxiang, additional, Li, Xin, additional, Manyam, Ganiraju C., additional, Wang, Xiao-xiao, additional, Xia, Yi, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Zhang, Li, additional, Montes-Moreno, Santiago, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhao, Xiaoying, additional, Møller, Michael B., additional, Parsons, Ben M., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2016
Full Text
View/download PDF

136. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma

Author

Ye, Qing, primary, Xu-Monette, Zijun Y., additional, Tzankov, Alexandar, additional, Deng, Lijuan, additional, Wang, Xiaoxiao, additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Montes-Moreno, Santiago, additional, Zhang, Li, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Parsons, Ben M., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Winter, Jane N., additional, Medeiros, L. Jeffrey, additional, Hu, Shimin, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

141. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma

Author

Li, Ling, primary, Xu-Monette, Zijun Y., additional, Ok, Chi Young, additional, Tzankov, Alexandar, additional, Manyam, Ganiraju C., additional, Sun, Ruifang, additional, Visco, Carlo, additional, Zhang, Mingzhi, additional, Montes-Moreno, Santiago, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Wang, Jinfen, additional, Parsons, Ben M., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Pham, Lan V., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

142. Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium

Author

Li, Ling, primary, Xu-Monette, Zijun Y., additional, Ok, Chi Y., additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Winter, Jane N., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

143. Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Liu, Zhiyu, primary, Xu-Monette, Zijun Y., additional, Cao, Xin, additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ai, Weiyun, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

144. Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program

Author

Shen, Qi, primary, Xu-Monette, Zijun Y., additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Cao, Xin, additional, Deng, Lijuan, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

145. Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Ye, Qinng, primary, Xu-Monette, Zijun Y., additional, Hu, Shimin, additional, Tzankov, Alexander, additional, Gisin, Nora, additional, Visco, Carlo, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Go, Ronald S., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

146. MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Manyam, Ganiraju C., additional, Tzankov, Alexander, additional, Deng, Qipan, additional, Visco, Carlo, additional, Tu, Meifeng, additional, Li, Ling, additional, Zu, Youli, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Farnen, John P., additional, Zhao, Xiaoying, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Miranda, Roberto N., additional, McDonnell, Timothy J., additional, Medeiros, L. Jeffrey, additional, Li, Yong, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

147. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?

Author

Ok, Chi Young, primary, Ye, Qing, additional, Li, Ling, additional, Manyam, Ganiraju C., additional, Deng, Lijuan, additional, Goswami, Rashmi R., additional, Wang, Xiaoxiao, additional, Montes-Moreno, Santiago, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Dybkaer, Karen, additional, Zhang, Li, additional, Abramson, Jeremy, additional, Sohani, Aliyah R., additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhang, Shanxiang, additional, Parsons, Ben M., additional, Xu, Mina, additional, Møller, Michael B., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Xu-Monette, Zijun Y., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

148. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries

Author

Xu-Monette, Zijun Y., primary, Tu, Meifeng, additional, Jabbar, Kausar J., additional, Cao, Xin, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Cai, Qingqing, additional, Montes-Moreno, Santiago, additional, An, Yuji, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhao, Xiaoying, additional, Møller, Michael B., additional, Farnen, John P., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Miranda, Roberto N., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

149. Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries

Author

Xu-Monette, Zijun Y., primary, Tu, Meifeng, additional, Jabbar, Kausar J., additional, Cao, Xin, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Nagarajan, Lalitha, additional, Cai, Qinging, additional, Montes-Moreno, Santiago, additional, An, Yuji, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhao, Xiaoying, additional, Møller, Michael B., additional, Farnen, John P., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Miranda, Roberto N., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results